Skip to main content
SpringerLink
Log in

Failure of somatostatin or an analog to promote closure of end pancreatic fistulae

  • Case Report
  • Published:
International journal of pancreatology Aims and scope Submit manuscript

Summary

Somatostatin has been reported to promote closure of pancreatic fistulae, but use of the analog SMS 201-995 (Sandoz, Inc.) has not previously been publishede We used this analog to treat two patients with end pancreatic fistulae refractory to conventional therapy. One patient had disruption of a pancreaticojejunostomy after pancreaticoduodenectomy and the other had acute necrotizing gallstone pancreatitis and disruption of the pancreatic duct in the tail. SMS 201-995 (100-150 μg/d) abruptly decreased fistula output by 50% in both patients but further increases in dosage had no further effect on output. Neither fistula healed after 3–4 wk of therapy. Treatment with somatostatin or its analogs alone will not lead to closure of a pancreatic fistula complicated by factors such as distal obstruction, infection, or foreign body. Somatostatin may promote closure of lateral fistulae and may simplify the management of patients with high output fistulae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Gullemin R. Hypothalmic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–79.

    Article  PubMed  CAS  Google Scholar 

  2. Brazeau P. Somatostatin: a peptide with unexpected physiological activities. Am. J. Med. 1986; 81(Suppl): 8–12.

    Article  PubMed  CAS  Google Scholar 

  3. Alberti KG, Christensen NJ, Christensen SE, et al. Inhibition of insulin secretion by somatostatin. Lancet 1973; 11: 1299–1301.

    Article  Google Scholar 

  4. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemo-dynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterol. 1981; 80: 581–525.

    Google Scholar 

  5. Bloom SF. Somatostatin and the gut. Gastroenterol. 1978; 75: 145–147.

    CAS  Google Scholar 

  6. Bloom SF, Mortimer CH, Thorner MO, et al. Inhibition of gastric acid secretion by growth hormone release inhibiting hormone. Lancet 1974; 2: 1106–1109.

    Article  PubMed  CAS  Google Scholar 

  7. Boden G, Sivitz MC, Owen OE, et al. Somatostatin suppresses secretin and pancreatic exocrine secretion. Science 1975; 190: 163–164.

    Article  PubMed  CAS  Google Scholar 

  8. Magnusson I, Ihre T, Johansson C, et al. Randomized double blind trial of somatostatin in the treatment of massive upper gastrointestinal hemorrhage. Gut 1985; 26: 221–226.

    Article  PubMed  CAS  Google Scholar 

  9. Mulvihill S, Pappas T, Passaro E, Debas H. The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery 1986; 100: 467–475.

    PubMed  CAS  Google Scholar 

  10. Hild P, Stoyanov M, Dobroshke J, Aigner K. Conservative treatment of fistulas of the pancreas and small intestine with somatostatin. Ann. Chir. 1982; 3: 193–196.

    Google Scholar 

  11. DiConstanzo J, Cano N, Martin J. Somatostatin in persistent gastrointestinal fistula treated by total parenteral nutrition. Lancet 1982; II: 338–339.

    Article  Google Scholar 

  12. Roncoroni L, Violi V, Montanari M, Muri M. Effect of somatostatin on exocrine pancreas evaluated on a total external pancreatic fistula of neoplastic origin. Am. J. Gastroenterol. 1983; 78: 425–428.

    PubMed  CAS  Google Scholar 

  13. Rich AJ, Sainsbury JR. Somatostatin in gastrointestinal fistulae (letter). Lancet 1986; I: 1981.

    Google Scholar 

  14. Rumi A, Testone G, Uggeri G. Critical evaluation of the protracted use of somatostatin in the conservative treatment of complex pancreaticoduodenal fistulas. Chir. Ital. 1983; 35: 1003–1013.

    PubMed  CAS  Google Scholar 

  15. Jost JO, Clemens M, Ruhland D, Bunte H. Somatostatin in pancreas and small intestine fistulas. Zentralbl-Chir. 1984; 109: 527–531.

    PubMed  CAS  Google Scholar 

  16. Kingsnorth AN, Moss JG, Small W. Failure of somatostatin to accelerate closure of enterocutaneous fistulas in patients receiving total parenteral nutrition (letter). Lancet 1986; I: 1271.

    Article  Google Scholar 

  17. Jackson I, Barnard L, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am. J. Med. 1986; 81(suppl): 94–101.

    Article  PubMed  CAS  Google Scholar 

  18. Kvols LK, Martin JK, Marsh HM, Moertel CG. Carcinoid crisis: rapid reversal of life threatening hypotension with a somatostatin analogue. N. EngL J. Med. 1985; 313: 1229–1230.

    PubMed  CAS  Google Scholar 

  19. Prinz RA, Pickleman J, Hoffman JP, Treatment of pancreatic cutaneous fistulae with a somatostatin analogue. Am. J. Surg. 1988; 155: 36–42.

    Article  PubMed  CAS  Google Scholar 

  20. Kohler E, Beglinger C, Ribes G, Grotzinger U, Loubatieres-Mariani MM, Gyr K. Effect of circulating somatostatin on exocrine pancreatic secretion in conscious dogs. Pancreas 1986; 1: 455–459.

    Article  PubMed  CAS  Google Scholar 

  21. Taparel D, Susini C, Esteve JP, Diaz J, Cazauban C, Vaysse N, Ribet A Somatostatin analogs: correlation of receptor affinity with inhibition of cyclic AMP formation in pancreatic acinar cells. Peptides 1985; 6: 109–113.

    Article  PubMed  CAS  Google Scholar 

  22. Goto Y, Garcia R, DeBas HT. Inhibitory pancreatic neurons mediate the inhibitory action of somatostatin (SS) on pancreatic exocrine secretion (abstract). Gastroenterol. 1987; 92(5) 2: 1410.

    Google Scholar 

  23. Pederzoli P, Bassi C, Falconi M, Albrigo R, Vantini I, Micciolo R. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon, or calcitonin. Surg. Gynecol. Obstet. 1986; 163: 428–432.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Departments of Surgery and Radiology, Virginia Mason Medical Center, 1100 Ninth Ave., 98111, Seattle, WA

    Bonnie M. Miller, L. William Traverso & Patrick C. Freeny

  2. Vanderbilt University Medical Center, 37232, Nashville, TN

    Naji N. Abumrad

Authors
  1. Bonnie M. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. William Traverso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick C. Freeny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naji N. Abumrad
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, B.M., Traverso, L.W., Freeny, P.C. et al. Failure of somatostatin or an analog to promote closure of end pancreatic fistulae. Int J Pancreatol 4, 65–72 (1989). https://doi.org/10.1007/BF02924148

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02924148

Key Words

Search

Navigation